5-MeO-AMT

5-MeO-AMT produces acute cardiovascular stimulation via monoamine release and reuptake inhibition. Its potent 5-HT2B agonism (EC50 4 nM) is mechanistically linked to cardiac valvulopathy with repeated exposure. Individuals with pre-existing arrhythmia or structural heart disease face elevated acute risk from sympathomimetic effects and elevated chronic risk from 5-HT2B-mediated fibrotic signalling.

5-MeO-AMT's sympathomimetic overdose profile includes seizures. Individuals with pre-existing seizure disorders face compounded risk. The compound's narrow therapeutic index means even moderate dose miscalculation could reach seizure-inducing levels.

Lithium co-administration with serotonergic psychedelics is associated with unpredictable potentiation and increased seizure risk. No specific data exist for the 5-MeO-AMT-lithium combination; this contraindication is extrapolated from class-level reports with LSD and psilocybin.

schizophrenia, schizoaffective disorder, bipolar I disorder

As a potent 5-HT2A agonist, 5-MeO-AMT carries the standard serotonergic psychedelic risk of precipitating psychosis in individuals with personal or family history of psychotic spectrum disorders. The compound's extended duration (12-18 hours) means any adverse psychological reaction persists far longer than with shorter-acting psychedelics.

5-MeO-AMT metabolism is expected to depend on CYP enzymes (primarily CYP2D6, by analogy with 5-MeO-DIPT). Hepatic impairment would reduce clearance, increasing plasma levels and extending duration in a compound already noted for its narrow therapeutic index. No direct pharmacokinetic data exist for 5-MeO-AMT in hepatically impaired populations.

No reproductive or developmental toxicity studies have been conducted for 5-MeO-AMT in any species. The compound's potent serotonergic activity and monoamine releasing properties present theoretical risk to fetal development. Contraindicated by precautionary principle.

Co-administration with any monoamine oxidase inhibitor — including irreversible MAOIs (phenelzine, tranylcypromine), reversible MAOIs (moclobemide), and MAOI-containing substances (ayahuasca, Syrian rue) — blocks the primary catabolic pathway for 5-MeO-AMT, drastically increasing plasma levels and duration. The resulting serotonin syndrome can be fatal. This is the single most dangerous pharmacological combination for this substance.

Co-administration with SSRIs or SNRIs creates additive serotonergic load. Malcolm & Thomas (2022) document serotonin syndrome risk from psychedelic-SSRI combinations. SSRIs may also reduce psychedelic effects via chronic 5-HT2A downregulation, potentially prompting users to escalate doses and increasing toxicity risk given the narrow therapeutic index.